197 related articles for article (PubMed ID: 21037081)
1. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
2. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.
Serra S; Zheng L; Hassan M; Phan AT; Woodhouse LJ; Yao JC; Ezzat S; Asa SL
Cancer Res; 2012 Nov; 72(22):5683-91. PubMed ID: 22986737
[TBL] [Abstract][Full Text] [Related]
3. Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast.
Dallol A; Buhmeida A; Merdad A; Al-Maghrabi J; Gari MA; Abu-Elmagd MM; Elaimi A; Assidi M; Chaudhary AG; Abuzenadah AM; Nedjadi T; Ermiah E; Alkhayyat SS; Al-Qahtani MH
Tumour Biol; 2015 Dec; 36(12):9677-83. PubMed ID: 26152288
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
6. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
Stadler CR; Knyazev P; Bange J; Ullrich A
Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
[TBL] [Abstract][Full Text] [Related]
8. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss of chromosomal arm 8p in breast cancer progression.
Anbazhagan R; Fujii H; Gabrielson E
Am J Pathol; 1998 Mar; 152(3):815-9. PubMed ID: 9502423
[TBL] [Abstract][Full Text] [Related]
11. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract][Full Text] [Related]
12. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.
Iobagiu C; Lambert C; Raica M; Lima S; Khaddage A; Peoc'h M; Genin C
Cancer Genet; 2015 Apr; 208(4):135-42. PubMed ID: 25979597
[TBL] [Abstract][Full Text] [Related]
14. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
Wistuba II; Tomlinson GE; Behrens C; Virmani A; Geradts J; Blum JL; Minna JD; Gazdar AF
Genes Chromosomes Cancer; 2000 Aug; 28(4):359-69. PubMed ID: 10862044
[TBL] [Abstract][Full Text] [Related]
15. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer.
Wei W; You Z; Sun S; Wang Y; Zhang X; Pang D; Jiang Y
Mol Carcinog; 2018 Aug; 57(8):988-996. PubMed ID: 29603419
[TBL] [Abstract][Full Text] [Related]
17. High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor.
Gupta S; Joshi K; Wig JD; Arora SK
Indian J Cancer; 2009; 46(4):303-10. PubMed ID: 19749460
[TBL] [Abstract][Full Text] [Related]
18. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
19. Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province.
Jiang Y; Sun S; Wei W; Ren Y; Liu J; Pang D
Oncotarget; 2015 Oct; 6(32):34023-9. PubMed ID: 26431494
[TBL] [Abstract][Full Text] [Related]
20. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange J; Prechtl D; Cheburkin Y; Specht K; Harbeck N; Schmitt M; Knyazeva T; Müller S; Gärtner S; Sures I; Wang H; Imyanitov E; Häring HU; Knayzev P; Iacobelli S; Höfler H; Ullrich A
Cancer Res; 2002 Feb; 62(3):840-7. PubMed ID: 11830541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
